错配修复基因2在膀胱尿路上皮癌中的表达及其临床预后

目的:研究错配修复基因2(hMSH2)在膀胱尿路上皮癌中的表达及其与临床预后的关系。方法:应用SP免疫组化法检测72例膀胱尿路上皮癌和49例膀胱正常黏膜组织中hMSH2的表达状况,分析不同膀胱尿路上皮癌患者临床病理特征的hMSH2蛋白阳性表达率,Kaplan-Meier生存分析膀胱尿路上皮癌hMSH2蛋白阳性表达与5年复发的关系。结果:在膀胱尿路上皮癌中hMSH2蛋白表达的阳性率为34.72%(25/72),低于正常膀胱黏膜的91.84%(45/49),差异有统计学意义(P<0.01);hMSH2蛋白表达阳性率在Ⅰ级膀胱尿路上皮癌中为44.4%(20/45),高于Ⅱ~Ⅲ级的18.51%(5/27),差异有统计学意义(P<0.05)。在膀胱尿路上皮癌临床分期Tis^T1期中hMSH2蛋白表达阳性表达率为43.48%(20/46),高于T2~T4期的19.23%(5/26),差异有统计学意义(P<0.05)。Kaplan-Meier生存分析显示hMSH2表达阳性者的5年复发率为19.35%(6/31),低于hMSH2表达阴性者的46.34%(19/41),差异有统计学意义(P<0.05)。结论:hMSH2蛋白在膀胱尿路上皮癌中表达较正常组织低,与其分化程度、临床分期及5年复发率有关,hMSH2可能参与了膀胱尿路上皮癌的演化和进展。

Expression and its Clinical Prognosis of hMSH2 in Bladder Urothelial Carcinoma

Objective To investigate the expression of hMSH2 in bladder urothelial carcinoma and its clinical prognosis.Methods SP immunohistochemistry was used to detect expression of hMSH2 in 72 cases of bladder urothelial carcinoma and 49 cases of bladder normal tissues.The results and the clinical data of bladder urothelial carcinoma were analyzed.Kaplan-Meier survival was used to analyze the relationship between hMSH2 and 5-year recurrence of bladder urothelial carcinoma.Results The positive rate of hMSH2 protein expression of bladder urothelial carcinoma and normal bladder tissue was respectively 34.72%(25/72)and 91.84%(45/49),hMSH2 protein expression positive rate were 44.4%(20/45)at levelⅠ,18.51%at levelⅡ-Ⅲ(5/27),the difference is significant between groups(P<0.05).The positive expression rates of hMSH2 protein in Tis^T1 and T2~T4 were respectively 43.48%(20/46)and 19.23%(5/26),the difference was significant(P<0.05).Kaplan-Meier survival analysis showed that the recurrence rate of hMSH2 expression and negative hMSH2 expression were respectively 19.35%(6/31)and 46.34%(19/41)in the 5-year follow-up,the difference was significant(P<0.05).Conclusion The decreased expression of hMSH2 protein in bladder urothelial carcinoma is related to its differentiation,clinical stage and 5-year recurrence.hMSH2 may be involved in the evolution and progression of bladder urothelial carcinoma.